Preoperative treatments of rectal cancers;Traitements préopératoires des cancers rectaux

Cancer/Radiotherapie

Volumn 11, Issue 6-7, 2007, Pages 349-352

  Bosset, J F ^a   Nguyen, F ^a   Bosset, M ^a   Servagi Vernat, S ^a   Sedrati, A ^a   Lorgis, V ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Preoperative treatment; Rectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; SHORT SURVEY; TREATMENT FAILURE; TREATMENT PLANNING;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; RECTUM; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN B COMPLEX;

EID: 36049045400     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2007.08.005     Document Type: Short Survey

References (22)

1. Bouvier A.M., Remontet L., Jougla E., Launoy G., Grosclaude P., Buémi A., et al. Incidence des cancers digestifs en France. Gastroenterol. Clin. Biol. 28 (2004) 877-878
2. Bosset J.F., Pavy J.J., Hamers H.P., Horiot J.C., Fabri M.C., Rougier P., et al. Determination of the optimal dose of 5-fluorouracil when combined with low dose D, L-Leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. Eur. J. Cancer 29A (1993) 1406-1410
3. Bosset J.F., Mantion G., Lorchel F., Magnin V., Pelissier E., Gérard J.P., et al. Adjuvant and neoadjuvant radiation therapy for rectal cancer. Semin. Oncol. 27 (2000) 60-65
4. Bosset J.F., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., Daban A., et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J. Clin. Oncol. 23 (2005) 5620-5627
5. Bosset J.F. Cancers du rectum : la chimiothérapie préopératoire, nouveau standard. Cancer Radioth 9 (2005) 137-139
6. Bosset J.F. Distal rectal cancer: sphincter sparing is also a challenge for the radiation oncologist. Radiother. Oncol. 80 (2006) 1-3
7. Bosset J.F., Collette L., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 355 (2006) 1114-1123
8. Calais G., Collette L., Mineur L., Maingon P., Radosevic-Jelic L., Daban A., et al. Predictors of disease-free survival after preoperative radio(chemo)therapy and complete resection of T3-T4 rectal cancer with or without adjuvant chemotherapy (EORTC 22921). Eur. J. Cancer Suppl 3 (2005) 171
9. Chau I., Brown G., Cunningham D., Tait D., Wotherspoon A., Norman A.R., et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J. Clin. Oncol. 24 (2006) 668-674
10. Collette L., Bosset J.F., Den Dulk M., Nguyen F., Mineur L., Maingon P., et al. Patients with curative resection of cT3-T4 rectal cancer after preoperative radio- or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? (EORTC trial 22921). J. Clin. Oncol. (2007) (in press)
11. Galandiuk S., Wieand H.S., Moertel G.C., Cha S.S., Fitzgibbons R.J., Pemberton J.H., et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg. Gynecol. Oncol. 174 (1992) 27-32
12. Gerard J.P., Conroy T., Bonnetain F., Bouché O., Chapet O., Closon-Dejardin M.T., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J. Clin. Oncol. 24 (2006) 4620-4625
13. Ghadimi B.M., Grade M., Difilippantonio M.J., Varma S., Simon R., Montagna C., et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J. Clin. Oncol. 23 (2005) 1826-1838
14. Heald R.J., Husband E.M., and Ryall R.D. The mesorectum in rectal cancer surgery: the clue to pelvic recurrence?. Br. J. Surg. 69 (1982) 613-616
15. Marijnen C.A.M., Peters K.C.M.J., Putter H., Klein Kranenbarg E., Stiggelbout A.M., Leer J.W.H., et al. Long-term results, toxicity and quality of life in the TME trial. Radiother. Oncol. 74 (2004) S127
16. Merkel S., Mansmann U., Siassi M., Papadopoulos T., Hohenberger W., Hermanek P., et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int. J. Colorectal Dis. 16 (2001) 298-304
17. National Institute of Health. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. Jama 264 (1990) 1444-1450
18. Raab R., Meyer H.J., and Werner U. Surgery for rectal cancer. In: Bleiberg H., Kemeny N., Rougier P., et al. (Eds). Colorectal cancer. A clinical guide to therapy (2002), Martin Dunitz Ltd, Londres 173-184
19. Rouanet P. Impact des traitements préopératoires (radiothérapie et chimiothérapie) dans la conservation sphinctérienne des cancers du très bas rectum. Cancer Radiother. 10 (2006) 457-555
20. Rullier E., and Sebag-Montefiore D. Sphincter saving is the primary objective for local treatment of cancer of the lower rectum. Lancet Oncol. 7 (2006) 775-777
21. Sauer R., Becker H., Hohenberger W., Rödel C., Wittekind C., Fietkau R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351 (2004) 1731-1740
22. Shirouzu K., Isomoto H., Morodomi T., et al. Distal spread of rectal cancer and optimal distal margin of resection for sphincter-preserving surgery. Cancer 76 (1995) 398-492